These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7772169)

  • 1. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
    Howell A; Robertson J
    Lancet; 1995 Apr; 345(8955):989-90. PubMed ID: 7772169
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
    Howell A; DeFriend D; Robertson J; Blamey R; Walton P
    Lancet; 1995 Jan; 345(8941):29-30. PubMed ID: 7799704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer.
    Dowsett M; Johnston SR; Iveson TJ; Smith IE
    Lancet; 1995 Feb; 345(8948):525. PubMed ID: 7861903
    [No Abstract]   [Full Text] [Related]  

  • 4. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
    Robertson JF
    Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):11-4. PubMed ID: 11900210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
    DeFriend DJ; Anderson E; Bell J; Wilks DP; West CM; Mansel RE; Howell A
    Br J Cancer; 1994 Aug; 70(2):204-11. PubMed ID: 8054267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fulvestrant (Faslodex): current status in the therapy of breast cancer.
    Bundred N; Howell A
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):151-60. PubMed ID: 12113237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.
    Ellis PA; Saccani-Jotti G; Clarke R; Johnston SR; Anderson E; Howell A; A'Hern R; Salter J; Detre S; Nicholson R; Robertson J; Smith IE; Dowsett M
    Int J Cancer; 1997 Aug; 72(4):608-13. PubMed ID: 9259399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antiestrogen shows promise in ER-positive breast cancers.
    Oncology (Williston Park); 1994 Aug; 8(8):58. PubMed ID: 7947003
    [No Abstract]   [Full Text] [Related]  

  • 9. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fulvestrant: a new agent in endocrine treatment for breast cancer].
    Juretić A; Sarić N; Bisof V; Basić-Koretić M
    Lijec Vjesn; 2006; 128(1-2):31-6. PubMed ID: 16640225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
    Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
    Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
    Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
    J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer.
    Nicholson RI; Gee JM; Manning DL; Wakeling AE; Montano MM; Katzenellenbogen BS
    Ann N Y Acad Sci; 1995 Jun; 761():148-63. PubMed ID: 7625718
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pure antiestrogen for treatment of advanced breast cancers].
    Nomura Y
    Nihon Rinsho; 2000 Apr; 58 Suppl():334-9. PubMed ID: 11026015
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospects for combining hormonal and nonhormonal growth factor inhibition.
    Wakeling AE; Nicholson RI; Gee JM
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4350s-4355s; discussion 4411s-4412s. PubMed ID: 11916224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
    Osborne CK; Wakeling A; Nicholson RI
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S2-6. PubMed ID: 15094757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE
    Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
    Howell A; Osborne CK; Morris C; Wakeling AE
    Cancer; 2000 Aug; 89(4):817-25. PubMed ID: 10951345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?
    Wakeling AE
    J Steroid Biochem Mol Biol; 1993 Dec; 47(1-6):107-14. PubMed ID: 8274423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faslodex (ICI 182780). an oestrogen receptor downregulator.
    Howell A
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S87-8. PubMed ID: 11056334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.